Tratamento do diabetes mellitus do tipo 2: novas opções

Araújo, Leila Maria Batista; Britto, Maria Margarida Santos; Cruz, Thomaz

doi:10.1590/s0004-27302000000600011

Cited by 35 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Destaca-se a metformina, do grupo das biguanidas, e as sulfonilureias. Os sintomas mais frequentemente encontrados com o uso dessas medicações são diarreia e vômitos, os quais levam a uma piora na qualidade de vida dos pacientes com DMT2 e pode resultar em não aderência ao tratamento da doença 15,[58][59][60] .…”

Section: Alterações Funcionais Gastrointestinais E Medicações Para Trunclassified

Mechanisms and factors associated with gastrointestinal symptoms in patients with diabetes mellitus

Rodrigues

Motta

2012

J Pediatr (Rio J)

View full text Add to dashboard Cite

Objectives: To present the main mechanisms that cause gastrointestinal symptoms in patients with diabetes mellitus, their frequency, and controversies as to their occurrence in children and adolescents.Sources: Non-systematic review of the literature conducted in the MEDLINE/PubMed and SciELO databases , as well as relevant book chapters. The most relevant and up-to-date articles on the topic were selected. Summary of the findings:Prevalence of diabetes mellitus has been increasing over the years in many countries. The complications caused by this disease in the digestive system, such as gastrointestinal symptoms (nausea, vomiting, abdominal pain, heartburn, dysphagia, constipation, diarrhea, and fecal incontinence) are well known. The pathogenesis of changes in the gastrointestinal functions in patients with diabetes mellitus is still being investigated at the same time as the role of the enteric nervous system and its neurotransmitters has gained significance. As a consequence of the complications in the digestive system, which damage the enteric nervous system, patients with diabetes mellitus may have specific gastrointestinal motility disorders, some of which may be of great relevance, such as diabetic gastroparesis, constipation, and diarrhea. Gastrointestinal dysfunction increases the morbidity of diabetes mellitus and worsens the quality of life of diabetic individuals. Conclusions:There are few studies addressing these problems in childhood and adolescence. Diabetes mellitus affects the digestive system over the years. Because this condition worsens the quality of life of diabetic individuals and leads to complications, attention must be paid to gastrointestinal symptoms when treating patients with diabetes mellitus. J Pediatr (Rio J). 2012;88(1):17-24:Diabetes mellitus, digestive signs and symptoms, gastrointestinal motility, etiology, child, adolescent. ResumoObjetivos: Apresentar a frequência, os principais fatores causadores dos sintomas gastrointestinais em pacientes portadores do diabetes melito e controvérsias quanto à sua ocorrência em crianças e adolescentes. Fontes dos dados:Revisão não sistemática nas bases de dados MEDLINE/PubMed e SciELO (1983-2011), além de capítulos de livros relevantes. Foram selecionados os artigos mais atuais e representativos do tema. Síntese dos dados:A prevalência do diabetes melito vem aumentando ao longo dos anos em vários países do mundo. No sistema digestório, é conhecida a ocorrência de complicações do diabetes melito, entre elas os sintomas gastrointestinais (náuseas, vômitos, dor abdominal, azia, disfagia, constipação, diarreia e incontinência fecal). A patogênese das alterações das funções gastrointestinais no diabetes melito está ainda sob investigação, e o papel do sistema nervoso entérico e seus neurotransmissores tem ganhado significância. Em decorrência do comprometimento do sistema digestório, com danos ao sistema nervoso entérico, portadores do diabetes melito podem apresentar quadros específicos de distúrbios de motilidade, alguns de grande re...

show abstract

Section: Alterações Funcionais Gastrointestinais E Medicações Para Trunclassified

Mechanisms and factors associated with gastrointestinal symptoms in patients with diabetes mellitus

Rodrigues

Motta

2012

J Pediatr (Rio J)

View full text Add to dashboard Cite

show abstract

“…The use of a hypoglycemic oral agent associated with insulin was observed in both survivors and deceased (26.6% vs. 45.5%). The use of this drug association generally occurs in patients with disease duration of approximately nine years, when metabolic control typically becomes inadequate [28]. This association may serve as a marker of mortality rates among DM patients in studies of drug use.…”

Section: Discussionmentioning

confidence: 99%

Drug Use Profile and Mortality in Patients with Diabetes Mellitus

Costa¹,

Pádua²,

Figueiredo³

et al. 2020

JPP

View full text Add to dashboard Cite

Objective: To analyze the medicine use by hospitalized patients with DM diagnosis and its association with mortality in one year follow up. Methods: Surveillance of all hospitalizations was conducted through the public health system in the mid-sized municipality of Minas Gerais, Brazil, for 18 weeks. Patients were interviewed regarding their socioeconomic, demographic, as well as medication use. Additionally, they were monitored regarding death outcomes. Deceased and survivors were compared using Multivariable analysis with Classification and Regression Tree. Results: During surveillance we identified 96 patients with DM diagnosis hospitalized, among these, 63 were interviewed regarding medication use. A total of 16 patients (28.1%) did reported difficulty in finding medication within the public health system, 22 (34.9%) did not use hypoglycemic drugs, and 25 (39.7%) had low medication adherence. We found high death outcomes during follow-up, when 32 patients had died (33.3%). The variables associated with death were: absence of information regarding the effects of discontinuing medication; dispensary location, polypharmacy; legal age of adulthood and number of children. Conclusions: This investigation describes problems related to the correct use of drugs by patients with DM who may be contributing to the frequent hospitalizations besides the high mortality rate in this population. These findings may prove useful in public policy planning for DM and may lead to a significant reduction in premature death.

show abstract

“…In addition to being associated with weight reduction, its effectiveness in glycemic control is similar to that of sulfonylurea [17]. Another advantage of metformin is that it does not induce hypoglycemia or stimulate insulin secretion [18].…”

Section: Metforminmentioning

confidence: 99%